FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults
Patients aged six and older now have access to SIMTRIYO, the first new-class ADHD medication approved by the FDA in decades.
Who reported it (5)
- Centanafadine's Route to FDA Review: A Clinical Path of the ADHD Medication Psychiatric Times · 47d ago broke it first
- Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older mykxlg.com · 47d ago
- FDA Rules Today on First New-Class ADHD Drug for Kids and Adults in Decades Medical Daily · 47d ago
- Otsuka's triple reuptake inhibitor Simtriyo wins FDA OK for ADHD FirstWord Pharma · 47d ago
- FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults Psychiatric Times · 47d ago broke it first
The brief
- Velocity & Diffusion: Coverage escalated across 4 distinct news outlets with 5 published articles, achieving a live velocity of 3.
- Primary Driver: Patients aged six and older now have access to SIMTRIYO, the first new-class ADHD medication approved by the FDA in decades.
- Predictive Outlook: Newsylist algorithmic models forecast this story will remain a dominant headline through tomorrow.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
The FDA has granted approval to Otsuka for the use of SIMTRIYO, or centanafadine, to treat attention-deficit hyperactivity disorder in children, adolescents, and adults. As a triple reuptake inhibitor, the drug marks the first medication in a new class for this condition in decades.
FirstWord Pharma notes the significance of the approval for the pharmaceutical market, given the drug's unique mechanism of action. While the agency has confirmed its regulatory green light for patients aged 6 years and older, coverage does not yet specify when the medication will reach commercial pharmacy shelves or the planned distribution timeline for healthcare providers.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (80% supported) Updated 43d ago.
Quick answers
What is SIMTRIYO?
SIMTRIYO is a triple reuptake inhibitor known as centanafadine, recently approved by the FDA as a new-class treatment for ADHD.
Who is eligible to use this medication?
The FDA approved the drug for the treatment of ADHD in children, adolescents, and adults aged 6 years and older.
Which company produces this drug?
Otsuka is the company that received FDA approval for the medication.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
People, places & organizations
Topics
Related trends
FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
The FDA has granted clearance to a new Alzheimer’s disease blood test developed by Roche and Eli Lilly.
UPS is investing $2 billion in international, healthcare and supply chain businesses
UPS has committed more than $2 billion to accelerate global logistics, targeting international, healthcare, and supply chain sectors.
US law to investigate foodborne illness outbreaks has been delayed for 15 years
A 15‑year freeze on a key food‑safety law is sparking congressional pressure as groups warn it hinders outbreak investigations.
Marketside soup sold at Walmart recalled over Listeria concerns: FDA
Marketside tomato bisque soup kits face a 29‑state recall over potential Listeria, hitting Walmart shoppers nationwide
Taylor Farms Voluntarily Recalls Fresh Jalapeños Over Salmonella Concerns
Taylor Farms recalls ready-to-eat foods and jalapeño products over salmonella concerns.
FDA approves 1st mRNA flu shot, from Moderna
The first mRNA-based influenza vaccine has received federal approval in the United States.